Long-term administration of olanzapine induces adiposity and increases hepatic fatty acid desaturation protein in female C۵۷BL/۶J mice

Publish Year: 1397
نوع سند: مقاله ژورنالی
زبان: English
View: 127

This Paper With 7 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJBMS-21-5_009

تاریخ نمایه سازی: 27 مهر 1400

Abstract:

Objective(s): Weight gain and metabolic disturbances such as dyslipidemia, are frequent side effects of second-generation antipsychotics, including olanzapine. This study examined the metabolic effects of chronic olanzapine exposure. In addition, we investigated the hepatic fatty acid effects of olanzapine in female C۵۷BL/۶J mice fed a normal diet.Materials and Methods: Female C۵۷BL/۶J mice orally received olanzapine or normal saline for ۷ weeks. The effects of long-term olanzapine exposure on body weight changes, food efficiency, blood glucose, triglyceride (TG), insulin, and leptin levels were observed. Hepatic TG and abdominal fat mass were investigated, and fat cell morphology was analyzed through histopathological methods. The levels of protein markers of fatty acid regulation in the liver, namely fatty acid synthase (FAS) and stearoyl-CoA desaturase-۱ (SCD-۱), were measured.Results: Olanzapine treatment increased the food intake of the mice as well as their body weight. Biochemical analyses showed that olanzapine increased blood TG, insulin, leptin, and hepatic TG. The olanzapine group exhibited increased abdominal fat mass and fat cell enlargement in abdominal fat tissue. Western blotting of the mouse liver revealed significantly higher (۱.۶-fold) levels of SCD-۱ in the olanzapine group relative to the control group; by contrast, FAS levels in the two groups did not differ significantly.Conclusion: Enhanced lipogenesis triggered by increased hepatic SCD-۱ activity might be a probable peripheral mechanism of olanzapine-induced dyslipidemia. Some adverse metabolic effects of olanzapine may be related to the disturbance of lipid homeostasis in the liver.

Authors

Po-Hsun Hou

Department of Veterinary Medicine, National Chung Hsing University, ۲۵۰ Kuo Kuang Road, Taichung ۴۰۲۲۷, Taiwan

Geng-Ruei Chang

Department of Veterinary Medicine, National Chung Hsing University, ۲۵۰ Kuo Kuang Road, Taichung ۴۰۲۲۷, Taiwan

Chin-Pin Chen

Department of Veterinary Medicine, National Chung Hsing University, ۲۵۰ Kuo Kuang Road, Taichung ۴۰۲۲۷, Taiwan

Yen-Ling Lin

Department of Veterinary Medicine, National Chung Hsing University, ۲۵۰ Kuo Kuang Road, Taichung ۴۰۲۲۷, Taiwan

I-Shuan Chao

Department of Veterinary Medicine, National Chung Hsing University, ۲۵۰ Kuo Kuang Road, Taichung ۴۰۲۲۷, Taiwan

Ting-Ting Shen

Department of Veterinary Medicine, National Chung Hsing University, ۲۵۰ Kuo Kuang Road, Taichung ۴۰۲۲۷, Taiwan

Frank Mao

Department of Veterinary Medicine, National Chung Hsing University, ۲۵۰ Kuo Kuang Road, Taichung ۴۰۲۲۷, Taiwan

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • de Leon J, Susce MT, Johnson M, Hardin M, Pointer ...
  • Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, Gebhardt N, Remschmidt H, ...
  • Rzewuska M. Metabolic risk during antipsychotic treatment in patients with ...
  • Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, ...
  • Kluge M, Schuld A, Himmerich H, Dalal M, Schacht A, ...
  • McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, ...
  • Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, ...
  • Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, ...
  • Haro JM, Novick D, Suarez D, Roca M. Antipsychotic treatment ...
  • Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain ...
  • Tighe S, Dinan T. An overview of the central control ...
  • Attie AD, Krauss RM, Gray-Keller MP, Brownlie A, Miyazaki M, ...
  • Miyazaki M, Kim YC, Gray-Keller MP, Attie AD, Ntambi JM. ...
  • Issandou M, Bouillot A, Brusq JM, Forest MC, Grillot D, ...
  • Flowers MT, Ntambi JM. Stearoyl-CoA desaturase and its relation to ...
  • Paillard F, Catheline D, Duff FL, Bouriel M, Deugnier Y, ...
  • Polymeropoulos MH, Licamele L, Volpi S, Mack K, Mitkus SN, ...
  • Lauressergues E, Staels B, Valeille K, Majd Z, Hum DW, ...
  • Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, ...
  • Vik-Mo AO, Birkenaes AB, Ferno J, Jonsdottir H, Andreassen OA, ...
  • Ferno J, Vik-Mo AO, Jassim G, Havik B, Berge K, ...
  • Coccurello R, Brina D, Caprioli A, Conti R, Ghirardi O, ...
  • Shertzer HG, Kendig EL, Nasrallah HA, Johansson E, Genter MB. ...
  • Yoon S, Noh JS, Choi SY, Baik JH. Effects of ...
  • Schmidt RH, Jokinen JD, Massey VL, Falkner KC, Shi X, ...
  • Spisni E, Tugnoli M, Ponticelli A, Mordenti T, Tomasi V. ...
  • Chang GR, Wu YY, Chiu YS, Chen WY, Liao JW, ...
  • Chang GR, Chen PL, Hou PH, Mao FC. Resveratrol protects ...
  • Chang GR, Chiu YS, Wu YY, Chen WY, Liao JW, ...
  • Chang GR, Chiu YS, Wu YY, Lin YC, Hou PH, ...
  • Arjona AA, Zhang SX, Adamson B, Wurtman RJ. An animal ...
  • Cope MB, Nagy TR, Fernandez JR, Geary N, Casey DE, ...
  • Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding ...
  • Kirk SL, Glazebrook J, Grayson B, Neill JC, Reynolds GP. ...
  • Weston-Green K, Huang XF, Lian J, Deng C. Effects of ...
  • Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. ...
  • Correll CU. Monitoring and management of antipsychotic-related metabolic and endocrine ...
  • Esen-Danaci A, Sarandol A, Taneli F, Yurtsever F, Ozlen N. ...
  • Zugno AI, Barcelos M, Oliveira L, Canever L, Luca RD, ...
  • Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin ...
  • Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, ...
  • Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, ...
  • Graham KA, Perkins DO, Edwards LJ, Barrier RC, Jr., Lieberman ...
  • Oriot P, Feys JL, Mertens de Wilmars S, Misson A, ...
  • Ryan MC, Flanagan S, Kinsella U, Keeling F, Thakore JH. ...
  • Fell MJ, Marshall KM, Williams J, Neill JC. Effects of ...
  • Chintoh AF, Mann SW, Lam TK, Giacca A, Remington G. ...
  • Minet-Ringuet J, Even PC, Valet P, Carpene C, Visentin V, ...
  • Victoriano M, de Beaurepaire R, Naour N, Guerre-Millo M, Quignard-Boulange ...
  • Baptista T, Araujo de Baptista E, Ying Kin NM, Beaulieu ...
  • Kang SH, Lee JI. Metabolic disturbances independent of body mass ...
  • Skrede S, Ferno J, Vazquez MJ, Fjaer S, Pavlin T, ...
  • Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, ...
  • Almeras N, Despres JP, Villeneuve J, Demers MF, Roy MA, ...
  • Vestri HS, Maianu L, Moellering DR, Garvey WT. Atypical antipsychotic ...
  • Cohen P, Ntambi JM, Friedman JM. Stearoyl-CoA desaturase-۱ and the ...
  • Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, Berja A, Garcia-Unzueta MT, ...
  • Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, ...
  • Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, ...
  • Chiu CC, Chen KP, Liu HC, Lu ML. The early ...
  • Weston-Green K, Huang XF, Deng C. Olanzapine treatment and metabolic ...
  • Spoelstra JA, Stolk RP, Cohen D, Klungel OH, Erkens JA, ...
  • van Winkel R, De Hert M, Wampers M, Van Eyck ...
  • Chiu CC, Chen CH, Chen BY, Yu SH, Lu ML. ...
  • Smith RC, Lindenmayer JP, Davis JM, Kelly E, Viviano TF, ...
  • Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, ...
  • Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, ...
  • Liao CH, Chang CS, Wei WC, Chang SN, Liao CC, ...
  • Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity ...
  • Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive ...
  • نمایش کامل مراجع